Faculty Mark W. Stolar, MD
|
|
- Marcus Gaines
- 5 years ago
- Views:
Transcription
1
2 Disclaimer This slide deck in its iginal and unaltered fmat is f educational purposes and is current as of November The content and views presented in this educational activity are those of the auths/presenters and do not necessarily reflect those of Creative Educational Concepts the suppter. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and offlabel uses of approved products. A qualified healthcare professional should be consulted befe using any therapeutic product discussed. Readers should verify all infmation and data befe treating patients employing any therapies strategies described in this educational activity.
3 Usage Rights This slide deck is provided f educational purposes and slides may be used f personal, non-commercial presentations only as long as content and references remain the same. No part of this slide deck may be published distributed in print electronic fmat without pri written permission from Creative Educational Concepts.
4 Faculty Mark W. Stolar, MD Associate Profess of Clinical Medicine Nthwestern University School of Medicine Chicago, IL
5 Disclosures to Participants (also located in participant handout materials) This Activity is Presented by Creative Educational Concepts, Inc. (CEC) an Accredited Continuing Medical Education Company. Conflicts of Interest and Financial Relationships Disclosures: Planners: Adrienne Matson, PharmD, BCPS nothing to disclose Auths/Presenters: Kate Mann, PharmD nothing to disclose Mark W. Stolar, MD is a member of the speakers bureaus f AstraZeneca, Sanofi, and Takeda. Peer Reviewer: Jeff Unger, MD, ABFM, FACE receives royalties from Lippincott; stockholder in Novo Ndisk; member of the speakers bureas f Janssen and Novo Ndisk; consultant f Abbott Diabetes, Halozyme, Itarcia, Janssen, and Novo Ndisk; and recieves research grants from GlaxoSmithKline, Lilly, and Merck. Commercial Suppt: This activity is suppted by an educational grant from Lilly. F further infmation concerning Lilly grant funding please visit
6 Prevalence, per 100 Persons per Year Prevalence Trends f Diagnosed Diabetes Adults Aged 20 to 79 years, United States, Observed Modeled Change in diagnostic criteria Year Geiss LS, et al. JAMA
7 Ambulaty Treatment of T2DM in U.S., Ambulaty visits f Diabetes, Millions Treatment of diabetes has grown in complexity while older treatments continue to be replaced supplemented by newer therapies. Turner LW, et al. Diabetes Care
8 Events per 10,000 Adult Population with Diagnosed Diabetes Changes in Diabetes-Related Complications (United States, ) Acute MI Stroke Amputation Much of the improvement in outcomes likely reflects me regular contact with health professionals and better management of care ESRD Death from Hyperglycemic Crisis MI=myocardial infarction; ESRD=end stage renal disease 1 Gregg EW, et al. N Engl J Med. 2014; 2 Yashkin AP, et al. Med Care
9 What s New in 2015
10 Modulation of the intensiveness of glucose lowering therapy in T2DM Patient/Disease Features Risks potentially associated with hypoglycemia and other drug adverse effects Approach to the Management of Hyperglycemia Me stringent Low A1C 7% Less stringent High Disease duration Newly diagnosed Long-standing Life expectancy Long Sht Usually not modifiable Imptant combidities Absent Few/Mild Severe Established vascular complications Absent Few/Mild Severe Patient attitude & expected treatment effts Resources & suppt system Highly motivated, adherent, excellent selfcare capacities Readily available Less motivated, non-adherent, po self-care capacities Potentially modifiable Limited Inzucchi SE, et al. Diabetes Care
11 AACE/ACE and ADA Goals f Glycemic Control: 2015 Treatment Target AACE/ACE ADA A1C 6.5%* <7.0% Fasting glucose Postprandial glucose Fasting and premeal plasma glucose: <110 mg/dl 2-hour postprandial glucose: <140 mg/dl Preprandial capillary plasma glucose: mg/dl Peak postprandial capillary plasma glucose : <180 mg/dl * Individualize on the basis of age, combidities, duration of disease, in general 6.5% f most; nmal f healthy; less stringent f less healthy Me less stringent glycemic goals may be appropriate f individual patients. Goals should be individualized based on duration of diabetes, age/life expectancy, combid conditions, known CVD advanced microvascular complications, hypoglycemia unawareness, and individual patient considerations. Postprandial glucose maybe targeted if A1C goals are not met despite reaching preprandial glucose goals. Postprandial glucose measurements should be made 1 2 h after the beginning of the meal, generally peak levels in patients with diabetes. AACE=American Association of Clinical Endocrinologists; ACE=American College of Endocrinology; 1 ADA=American Diabetes Association Handelsman Y, et al. Endocr Pract. 2015; American Diabetes Association. 2 American Diabetes Association. Diabetes Care
12 Pharmacological Therapy Selection Considerations Efficacy (effects on A1C, FBG, PPG) Hypoglycemia risk Effect on weight Mechanism of action Likely adherence Route of administration Ease of use Patient preference Cost Adverse effects/tolerability Effect on nonglycemic facts (eg, serum lipids, blood pressure) Contraindications from combidities (eg, hepatic renal impairment, cardiovascular disease) FBG=fasting blood glucose; PPG=postprandial plasma glucose American Diabetes Association. Diabetes Care
13 Monotherapy Dual therapy Efficacy * Hypo risk Weight Side effects Costs Efficacy * Hypo risk Weight Side effects Costs Healthy eating, weight control, increased physical activity & diabetes education Metfmin high low risk neutral/loss GI/lactic acidosis low If HbA1c target not achieved after ~3 months of monotherapy, proceed to 2-drug combination (der not meant to denote any specific preference - choice dependent on a variety of patient- & disease-specific facts): Metfmin Sulfonylurea high moderate risk gain hypoglycemia low Metfmin Thiazolidinedione high low risk gain edema, HF, fxs low Metfmin DPP-4 inhibit intermediate low risk neutral rare high Metfmin SGLT2 inhibit intermediate low risk loss GU, dehydration high Metfmin GLP-1 recept agonist high low risk loss GI high Metfmin Insulin (basal) highest high risk gain hypoglycemia variable If HbA1c target not achieved after ~3 months of dual therapy, proceed to 3-drug combination (der not meant to denote any specific preference - choice dependent on a variety of patient- & disease-specific facts): Triple therapy Metfmin Sulfonylurea TZD Metfmin Thiazolidinedione SU Metfmin DPP-4 Inhibit SU Metfmin SGLT-2 Inhibit SU Metfmin GLP-1 recept agonist SU Metfmin Insulin (basal) TZD DPP-4-i DPP-4-i TZD TZD TZD DPP-4-i SGLT2-i SGLT2-i SGLT2-i DPP-4-i Insulin SGLT2-i GLP-1-RA GLP-1-RA Insulin Insulin GLP-1-RA Insulin Insulin Combination injectable therapy If HbA1c target not achieved after ~3 months of triple therapy and patient (1) on al combination, move to injectables, (2) on GLP-1 RA, add basal insulin, (3) on optimally titrated basal insulin, add GLP-1-RA mealtime insulin. In refracty patients consider adding TZD SGLT2-i: Metfmin Basal Insulin Mealtime Insulin GLP-1-RA Inzucchi SE, et al. Diabetes Care
14 ADA/EASD Position Statement Update: Management of Hyperglycemia in T2DM, 2015 Patient-Centered Approach...providing care that is respectful of and responsive to individual patient preferences, needs, and values - ensuring that patient values guide all clinical decisions. Gauge patient s preferred level of involvement Exple, where possible, therapeutic choices Consider using decision aids Shared Decision Making a collabative process between patient and clinician, using best available evidence and taking into account the patient s preferences and values Final decisions regarding lifestyle choices ultimately lie with the patient Inzucchi SE, et al. Diabetes Care
15 Promote Self-Management Self-Management Education (SME) should be discussed at every diabetes-focused visit and individualized accding to type of diabetes, patient ability, and motivation f learning and change Set S.M.A.R.T. Goals Specific Measurable Achievable Realistic Timely Self-Management Areas of Focus Diabetes Education Nutrition Physical Activity Weight loss (5-10% of initial weight) Medication Hypoglycemia Self-Moniting Blood Glucose (SMBG) Foot Care Mental Health & Mood Disders Smoking Cessation Collabate with your patient to create an action plan on their identified area of focus Enable timely, culturally and literacy appropriate diabetes education and resources Encourage comprehensive visit with RD CDE within 1 year of diagnosis per ADA guidelines Minimum 150 minutes aerobic activity per week and resistance exercise 2-3 times per week Can substantially improve glycemic control and cardiovascular disease risk facts in overweight patients Counsel about adherence (dose, timing, frequency), anticipated effects, and mechanism of action Counsel about the prevention, recognition, and treatment of drug-induced hypoglycemia Not on insulin: Individualized to type of antihyperglycemic agents, level of control, and risk of hypoglycemia On insulin only once a day: SMBG once a day at variable times On insulin >once a day: SMBG 3 times per day including pre- and post-prandial values Educate on proper foot care including daily foot inspection Screen f depressive and anxious symptoms by interview a standardized questionnaire (eg, PHQ-9) Include fmal smoking prevention and cessation counseling Inzucchi SE, et al. Diabetes Care
16
17 Case Study: Consuela 47-year-old Latin American female with 3 year histy of T2DM presents f follow-up. Hypertension and dyslipidemia both controlled on medications. No histy of CVD. Recent histy of genital yeast infection treated with fluconazole. Currently on metfmin 1,000 mg BID and attempting to follow lifestyle interventions, weight=210 lbs, height 5 10 (BMI=30.1 kg/m 2 ). A1C initially decreased from 8% to 7% after starting metfmin therapy two years ago. However, today in clinic her A1C is up to 7.8%. CVD=cardiovascular disease; BMI=body mass index
18 Case Study: Consuela She also tells you she doesn t want to take any medication that may make her gain weight What agent would you select f her now?
19 Monotherapy Efficacy * Hypo risk Weight Side effects Costs Dual therapy Efficacy * Hypo risk Weight Side effects Costs Metfmin Sulfonylurea high moderate risk gain hypoglycemia low Healthy eating, weight control, increased physical activity & diabetes education Metfmin high low risk neutral/loss GI / lactic acidosis low If HbA1c target not achieved after ~3 months of monotherapy, proceed to 2-drug combination (der not meant to denote any specific preference - choice dependent on a variety of patient- & disease-specific facts): Metfmin high low risk gain edema, HF, fxs low Metfmin DPP-4 inhibit intermediate low risk neutral rare high Metfmin SGLT2 inhibit intermediate low risk loss GU, dehydration high Metfmin GLP-1 recept agonist high low risk loss GI high Metfmin Insulin (basal) highest high risk gain hypoglycemia variable Triple therapy Metfmin Sulfonylurea TZD If HbA1c target not achieved after ~3 months of dual therapy, proceed to 3-drug combination (der not meant to denote any specific preference - choice dependent on a variety of patient- & disease-specific facts): Metfmin Thiazolidinedione Thiazolidinedione SU Metfmin DPP-4 Inhibit SU Metfmin SGLT-2 Inhibit SU Metfmin GLP-1 recept agonist SU Metfmin Insulin (basal) TZD DPP-4-i DPP-4-i TZD TZD TZD DPP-4-i SGLT2-i SGLT2-i SGLT2-i DPP-4-i Insulin SGLT2-i GLP-1-RA GLP-1-RA Insulin Insulin GLP-1-RA Insulin Insulin Combination injectable therapy If HbA1c target not achieved after ~3 months of triple therapy and patient (1) on al combination, move to injectables, (2) on GLP-1 RA, add basal insulin, (3) on optimally titrated basal insulin, add GLP-1-RA mealtime insulin. In refracty patients consider adding TZD SGLT2-i: Metfmin Figure 2B. Anti-hyperglycemic therapy in T2DM: Avoidance of weight gain Mealtime Insulin Basal Insulin GLP-1-RA Inzucchi SE, et al. Diabetes Care
20 Multifactial Nature of Hyperglycemia in T2DM Dictates Need f Multiple Mechanisms of Action Impaired insulin secretion SUs Glinides TZDs Increased glucagon secretion DPP-4 inhibits GLP-1 RAs DPP-4 inhibits GLP-1 RAs Islet α-cell Islet β-cell Hyperglycemia Decreased incretin effect DPP-4 inhibits GLP-1 RAs Increased lipolysis Insulin TZDs Increased glucose reabsption via kidney Insulin SGLT2 inhibits Increased hepatic glucose production Insulin MET TZDs DPP-4=dipeptidyl peptidase-4; GLP-1 RA=glucagon-like peptide-1 recept agonist; MET=metfmin; SU=sulfonylurea; TZD=thiazolidinedione Neurotransmitter dysfunction Bromocriptine Decreased glucose uptake Insulin MET TZDs DeFronzo RA. Diabetes
21 Role of Incretins in Glucose Homeostasis Ingestion of food GI tract Inactive GLP-1 Release of gut hmones Incretins Active GLP-1 & GIP DPP-4 enzyme Inactive GIP DPP-4=dipeptidyl peptidase-4 GIP=glucose-dependent insulinotropic peptide GLP-1=glucagon-like peptide-1 Beta cells Alpha cells Pancreas Glucosedependent insulin from beta cells (GLP-1, GIP) Glucose dependent glucagon from alpha cells (GLP-1) Glucose uptake by muscles Glucose production by liver Blood Glucose Kieffer TJ, et al. Endocrinology. 1995; Ahrén B. Curr Diab Rep. 2003; Drucker DJ. Diabetes Care. 2003; Holst JJ. Metab Res Rev
22 Baggio LL, Drucker DJ. Gastroenterology
23 2-Hour Postprandial Plasma Level (pm) GLP-1 Activity Is Higher With GLP-1 RAs Than With DPP-4 Inhibits 75 Baseline Sitagliptin Exenatide twice daily Added GLP-1 Activity Endogenous GLP-1 Activity N=61 metfmin-treated, evaluable patients. DeFronzo RA, et al. Curr Med Res Opin
24 Once Weekly Exenatide vs. Twice Daily Exenatide DURATION-1 Trial 0 A1C Reductions (%) P= Fasting Plasma Glucose Reductions (mg/dl) P< Exenatide 2 mg once weekly -1.5 Exenatide 10 mcg twice daily Exenatide 10 mcg twice daily Exenatide 2 mg once weekly Nausea: Exenatide once weekly, 26.4% of patients vs, 34.5% of patients f twice daily Drucker D, et al. Lancet 2008.
25 Weight (kg) A1C (%) A1C and Weight Change With Sitagliptin vs. Liraglutide Exenatide QW Added to Metfmin * SITA LIRA 1.2 mg LIRA 1.8 mg EXN QW week trial (N=658) 1, BL A1C (%): ,** week trial (N=491) 2 BL A1C (%): * All as add-on to MET; Results sustained over 52 weeks 3 ; P<.05 vs. SITA; ** P<.0013 vs. LIRA 1.2 mg 1 Pratley RE, et al. Lancet. 2010;375: ; 2 Bergenstal RM, et al. Lancet. 2010;376: ; 3 Pratley R, et al. Int J Clin Pract. 2011;65:
26 LS Change in A1C (%) A1C and Weight Change with Sitagliptin vs. Dulaglutide Once Weekly added to Metfmin after 52 weeks (AWARD-5) LS Change in Weight A1C Reductions (%) Weight Loss (kg) P<.001 P< Dulaglutide mg Dulaglutide 1.5 mg Sitagliptin 100 mg Dulaglutide 1.5 mg -2.6 Dulaglutide 0.75 mg Sitagliptin 100 mg Nauck M, et al. Diabetes Care
27 A GLP-1 RA is selected f Consuela
28 Clinical Inertia to Initiation and Intensification of Injectable Therapies Self-blame Less with histy of better adherence, less DM stress Avoidance of injections Concerns of risk Hypoglycemic effects Complexity of regimens Misconceptions about complications Weight gain Skepticism of efficacy Negative impact on social life Karter A, et al. Diabetes Care. 2010;33: ; Peyrot M, et al. Diabetes Care. 2005;28:
29 Clinician Barriers/Resistance Complexity of training/availability of resources Time facts Resources (educats) Weight gain Perception of patient failure Age facts Fear of hypoglycemia Peyrot M, et al. Diabetes Care. 2005;28:
30 Suggestions f Overcoming Fear of Injections Dry run injection (Insert needle without injecting drug) Reinfce that injection is relatively painless Injection is into fatty tissue versus muscle Reinfce that injection is easy Injection devices are quick and easy-to-use Have pen available f demonstration
31 GLP-1 Recept Agonists Exenatide 5-10 mcg twice daily (Byetta 2005) 2 mg once weekly (Bydureon 2012) Liraglutide mg daily (Victoza 2010) 3 mg daily (weight loss indication, Saxenda 2014) Albiglutide mg once weekly (Tanzeum 2014) Dulaglutide mg once weekly (Trulicity 2014) Lixisenatide (submitted to the FDA September 2015)
32 GLP-1 Recept Agonists Exenatide, Exenatide LAR, Liraglutide, Albiglutide, Dulaglutide Mechanism Primary physiological action(s) Advantages Limitations Cost Activates GLP-1 recepts glucose-dependent insulin secretion glucose-dependent glucagon secretion Satiety Slows gastric emptying Postprandial glucose excursions Weight Patient training requirements (injectable therapy) Gastrointestinal side effects (nausea, vomiting [less with longer-acting agents]) Hypoglycemia possible when used with insulin, if insulin doses are not reduced High (relative to other generic agents, ie metfmin) Inzucchi SE, et al. Diabetes Care 2015.
33 Once Weekly Exenatide vs. Twice Daily Exenatide DURATION-1 Trial 0 A1C Reductions (%) P= Fasting Plasma Glucose Reductions (mg/dl) P< Exenatide 2 mg once weekly -1.5 Exenatide 10 mcg twice daily Exenatide 10 mcg twice daily Exenatide 2 mg once weekly Nausea: Exenatide once weekly, 26.4% of patients vs, 34.5% of patients f twice daily Drucker D, et al. Lancet 2008.
34 Once-Weekly Albiglutide vs. Once-Daily Liraglutide in Patients with T2DM: HARMONY-7 Trial Change in A1C (%) P= Albiglutide 30 mg once weekly Liraglutide titrated to 1.8 mg daily Injection site reactions were me common in albiglutide-treated patients, 12 9% vs 5 4%, P=.0002 Gastrointestinal Adverse Effects (% of patients experiencing) Albiglutide P= Liraglutide Pratley RE, et al. Lancet Diabetes Endocrinol
35 Dulaglutide Once-Weekly vs. Liraglutide Once-Daily: AWARD-6 in Metfmin-Treated Patients Open label noninferiity trial N=599 P noninferiity <.0001 Once-weekly dulaglutide 1.5 mg Once-daily liraglutide 1.8 mg A1C % reduction 0.34 Hypoglycemia events/year Maximum dose once-weekly dulaglutide is non-inferi to maximum dose once-daily liraglutide with low hypoglycemia events in both treatment groups Dungan K, et al. Lancet
36 Case Study 2: Two years later, she is admitted to the hospital f pneumonia She is currently taking a GLP-1 RA and metfmin Her A1C at this time is 7.6%; Her admission blood glucose is 190 mg/dl Her GLP-1 RA is stopped on admission and she is placed on basal insulin with crection fact prandial insulin She is discharged home on 18 units of basal insulin detemir (~0.2 units/kg) and metfmin
37 What would you tell her if she calls your office the next mning after discharge and asks if she can just restart her GLP-1 RA instead of taking the insulin?
38 Basal Insulin vs. GLP-1 RA
39 A1C (%) GLP-1 RAs Added to Multiple Oral Agents: Comparisons With Basal Insulin 0 MET SU (N=535) OADs (N=235) MET GLIM (N=576) MET ± SU (N=456) 4,* 5, MET ± SU (N = 216) Noninferi vs. insulin -1.3 P=NS vs. insulin P=.0015 vs. insulin P<.05 vs. insulin P<.0001 vs. insulin GLAR EXN BID LIRA EXN QW IDET * 70% on MET monotherapy background 70% on MET SU background 1 Heine R, et al. Ann Intern Med. 2005;143: ; 2 Davies M, et a. Diabetes Obes Metab. 2009;11: ; 3 Russell-Jones D, et al. Diabetologia. 2009;52: ; 4 Diamant M, et al. Lancet. 2010;375: ; 5 Davies M, et al. Diabetes Care. 2013;36:
40 Comparisons of Dulaglutide vs. Basal Insulin, Both in Combination with Prandial Insulin, in Patients with T2DM A1C % Reductions (%) Dulaglutide 0.75 mg onceweekly Dulaglutide 1.5 mg onceweekly Blonde L, et al. Lancet Insulin glargine, given at bedtime 20% 18% 16% 14% 12% 10% 8% 6% 4% 2% 0% Percent of Patients with Serious Adverse Events 9% 15% Dulaglutide Dulaglutide 1.5 mg onceweekly once-weekly 0.75 mg (N=27) (N=44) 18% Insulin glargine, given at bedtime (N=54)
41 Case Study: Consuela After discussing her options she actually decides to continue the insulin detemir since she already got the prescription filled. She agrees to follow-up with the diabetes nurse educat f instructions on selftitration.
42 Case Study: Consuela 3 months later she presents to her PCP office f follow-up Her A1C=7.8% on metfmin 1000 mg BID and insulin detemir 30 units QHS (~0.4 units/kg) She is compliant with her insulin therapy and has been successful with self-titration She has been checking her blood sugar every mning and her FBG range from mg/dl
43 Inzucchi S, et al. Diabetes Care # Injections 1 Approach to Starting and Adjusting Insulin in T2DM Basal Insulin (usually with metfmin /- other noninsulin agent) Start: 10 U/day U/kg/day Adjust: 1-15% 2-4 U once-twice weekly to reach FBG target F hypo: Determine and address cause: dose by 4 U 10-20% Complexity Low 2 3 Add 1 rapid insulin injection befe largest meal Start: 4 U, 0.1 U/kg, 10% basal dose. If A1C<8%, consider basal by same amount Adjust: dose by 1-2 U 10-15% once-twice weekly until SMBG target reached F hypo: Determine and address cause: cresponding dose by 2-4 U 10-20% If not controlled, consider basal-bolus If not controlled after FBG target is reached ( if dose >0.5 U/kg/day), treat PPG excursions with mealtime insulin (Consider initial GLP-1 RA trial) Add 2 rapid insulin injections befe meals ( basal-bolus ) Start: 4 U, 0.1 U/kg, 10% basal dose/meal. If A1C<8%, consider basal by same amount Adjust: dose by 1-2 U 10-15% once-twice weekly until SMBG target reached F hypo: Determine and address cause; cresponding dose by 2-4 U 10-20% Change to premixed insulin twice daily Start: Divide current basal dose into 2/3 AM, 1/3 PM 1/2 AM, 1/2 PM Adjust: dose by 1-2 U 10-15% oncetwice weekly until SMBG target reached F hypo: Determine and address cause: cresponding dose by 2-4 U 10-20% If not controlled, consider basal-bolus Mod. High Flexibility Me flexible Less flexible
44 Garber AJ, et al. Endocr Pract. 2013;19(2):
45 After Basal Insulin, Once-Weekly GLP-1 RA vs. Three Times Daily Prandial Insulin A1C Control Rosenstock J, et al. Diabetes Care
46 After Basal Insulin, Once-Weekly GLP-1 RA vs. Three Times Daily Prandial Insulin Weight Rosenstock J, et al. Diabetes Care
47 Rationale f GLP-1 Recept Agonists and Insulin The combination of a GLP-1RA and insulin may be highly effective f optimal glucose control, ameliating the adverse effects often associated with insulin Data from clinical studies suppt the therapeutic potential of GLP-1RA-insulin combination therapy, typically showing beneficial effects on: glycemic control body weight with a low incidence of hypoglycemia and, in established insulin therapy, facilitating reductions in insulin dose
48 One-year Sustained Glycemic Control and Weight Loss After Adding Basal Insulin to GLP-1 RA Rosenstock J, et al. Diabetes Complications
49 GI Adverse Events Pancreatitis Pancreatic Cancer Medullary Thyroid Cancer Renal Impairment Safety Considerations with GLP-1 Recept Agonist Common Usually dose dependent, transient with GLP-1 RAs Usually reduced with dose titration Patients should be counseled that pancreatitis has been repted with postmarketing use of some of these agents Labeling f all agents states that these agents should be immediately discontinued if pancreatitis suspected Labeling f liraglutide states that caution and appropriate moniting be used in patients with a histy of pancreatitis Albiglutide, dulaglutide, exenatide, and exenatide LAR labeling note that alternate antidiabetic therapy be used in patients with a histy of pancreatitis Further assessments required from long duration-controlled studies epidemiological databases Black Box Warning with albiglutide, dulaglutide, liraglutide, exenatide LAR; Patients should be counseled regarding the risk of medullary thyroid carcinoma and the symptoms of thyroid tums Contraindicated in patients with personal/family histy, patients with multiple endocrine neoplasia syndrome type 2 Renal impairment has been repted postmarketing, usually in association with nausea, vomiting, diarrhea, dehydration. Use caution when initiating escalating doses in patients with renal impairment. Exenatide should not be used in patients with severe renal insufficiency end stage renal disease Despite rarity of some of these safety issues, they are also serious in nature. Helpful to discuss these issues early on in therapy up front without minimizing patients concerns but putting them into perspective. Fineman MS, et al. Diabetes Obes Metab. 2012; FDA Prescribing Infmation.
50 GLP-1 Dosing Devices Drug Dosing Frequency How Supplied Comments Albiglutide Dulaglutide Exenatide Exenatide LAR (once weekly) Liraglutide Once a week on the same day each week, any time of the day, without regard to meals Once weekly at any time of day, with without food 60 minutes pri to mning and evening meals, befe the 2 main meals of the day, about 6 hours me apart Once every 7 days (weekly) at any time of day, with without meals One time each day, at any time during the day, without regard to food Single-dose pen f SQ injection Solution in a singledose pen f SQ injection Solution in a singledose prefilled syringe f SQ injection Multi-dose pen f SQ injection Single-dose pen f SQ injection Single-dose tray containing vial/syringe f SQ injection Pre-filled, multi-dose pen f SQ injection Must be reconstituted, use within 8 hours after reconstitution, may ste in refrigerat until expiration date at room temperature f 4 weeks Refrigerate, may be kept at room temperature f a total of 14 days Refrigerate, may ste at room temperature after first use, discard 30 days after first use Must be reconstituted, administer immediately after reconstitution, ste in refrigerat until preparing f use Refrigerate, may ste at room temperature after first use, discard 30 days after first use SQ=subcutaneous FDA Prescribing Infmation.
51 Medication Exenatide (twice daily) Renal Dosing Adjustment Required Not recommended in endstage renal disease in severe renal impairment (CrCl <30 ml/min). In moderate renal impairment (CrCl ml/min) caution should be exercised when initiating increasing the dose of exenatide from 5 mcg to 10 mcg. Hepatic Dosing Adjustment Liraglutide No No Exenatide LAR (once weekly) Not recommended in endstage renal disease in severe renal impairment (CrCl <30 ml/min). In moderate renal impairment (CrCl ml/min) renal transplantation use caution. Albiglutide No No Dulaglutide If a patient with severe renal impairment end-stage renal disease experiences adverse gastrointestinal side effects, monit renal function closely. No No No Drug Interactions Orally administered medications with a narrow therapeutic index require rapid GI absption may be affected by exenatide-induced delayed gastric emptying, use with caution Oral hmonal contraceptives and antibiotics should be used be taken 1 hour befe exenatide injection Warfarin, monit INR closely Orally administered medications may be affected by liraglutide-induced delayed gastric emptying, use with caution Orally administered medications may be affected by exenatide-induced delayed gastric emptying, use with caution Orally administered medications may be effected by albiglutide-induced delayed gastric emptying, use with caution Orally administered medications with a narrow therapeutic index may be affected by dulaglutide-induced delayed gastric emptying, use with caution Pregnancy Categy C C C C C FDA Prescribing Infmation.
52 Questions?
Insulin and Post Prandial
Insulin and Post Prandial Pr Luc Martinez PCDE Meeting Barcelona 2016 Conflicts of interest disclosure Advis consultant f Amgen Inc.; AstraZeneca Pharmaceuticals LP; GlaxoSmithKline; Ipsen; Lilly; Mayoly
More informationMultiple Factors Should Be Considered When Setting a Glycemic Goal
Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent
More informationPathogenesis of Type 2 Diabetes
9/23/215 Multiple, Complex Pathophysiological Abnmalities in T2DM incretin effect gut carbohydrate delivery & absption pancreatic insulin secretion pancreatic glucagon secretion HYPERGLYCEMIA? Pathogenesis
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationManagement of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association (ADA) and the European Association f the Study of Diabetes
More informationProgressive Loss of β-cell Function in T2DM
Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of November 2015. The content and views presented in this educational activity are those of
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationAdvances in Outpatient Diabetes Care: Algorithms for Care and the Role of Injectable Therapies. Module D
Advances in Outpatient Diabetes Care: Algorithms for Care and the Role of Injectable Therapies Module D 1 Learning Objectives Apply the principles of the comprehensive diabetes algorithms to patients with
More informationA Blueprint for Optimizing Diabetes Management: Implementing Guidelines in Practice
1 Disclaimer This slide deck in its iginal and unaltered fmat is f educational purposes and is current as of November 2015. The content and views presented in this educational activity are those of the
More informationSilvio E. Inzucchi MD Section of Endocrinology Yale School of Medicine
Gegia Chapter of the American Association of Clinical Endocrinologists, 2017 Annual Meeting January 28, 2017 Silvio E. Inzucchi MD Section of Endocrinology Yale School of Medicine DIABETES MANAGEMENT GUIDELINES
More informationPresented By: Creative Educational Concepts, Inc. Lexington, KY
Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of April 2015. The content and views presented in this educational activity are those of the
More informationThis program applies to Commercial, GenPlus and Health Insurance Marketplace formularies.
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) Agonists [Adlyxin (lixisenatide), Byetta (exenatide), Bydureon (exenatide extended-release), Tanzeum (albiglutide), Trulicity (dulaglutide),
More informationINJECTABLE THERAPY FOR THE TREATMENT OF DIABETES
INJECTABLE THERAPY FOR THE TREATMENT OF DIABETES ARSHNA SANGHRAJKA DIABETES SPECIALIST PRESCRIBING PHARMACIST OBJECTIVES EXPLORE THE TYPES OF INSULIN AND INJECTABLE DIABETES TREATMENTS AND DEVICES AVAILABLE
More informationDM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My!
DM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My! Kevin M. Pantalone, DO, ECNU, CCD Associate Staff Director of Clinical Research Department of Endocrinology Endocrinology and
More informationDiabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items
Diabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items Hayley A. Miller, MD Physician, Internal Medicine, Diabetes and Metabolism, Sandy Clinic, Intermountain Healthcare Objectives:
More informationInitiating Injectable Therapy in Type 2 Diabetes
Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current
More informationAchieving and maintaining good glycemic control is an
Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE; Kathleen Wyne, MD, PhD, FACE, FNLA; Anthony Cannon,
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More informationGLP-1 receptor agonists for type 2 diabetes currently available in the U.S.
GLP-1 receptor agonists for type 2 diabetes currently available in the U.S. GLP-1 agonists are a class of antidiabetic agents that mimic the actions of the glucagon-like peptide. GLP-1 is one of several
More informationDiabetes: Three Core Deficits
Diabetes: Three Core Deficits Fat Cell Dysfunction Impaired Incretin Function Impaired Appetite Suppression Obesity and Insulin Resistance in Muscle and Liver Hyperglycemia Impaired Insulin Secretion Islet
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationGlucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol
Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationReviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate
Reviewing Diabetes Guidelines Newsletter compiled by Danny Jaek, Pharm.D. Candidate AL AS KA N AT IV E DI AB ET ES TE A M Volume 6, Issue 1 Spring 2011 Dia bet es Dis pat ch There are nearly 24 million
More informationBeyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM
Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM Disclosures Jennifer D Souza has no conflicts of interest to disclose. 2 When Basal Insulin Is Not Enough Learning
More informationGLP-1-based therapies in the management of type 2 diabetes
GLP-1-based therapies in the management of type 2 diabetes Makbul Aman Mansyur Division Endocrine & Metabolism Department of Internal Medicine Faculty of Medicine Hasanuddin University/ RSUP Dr. Wahidin
More informationGLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION.
GLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION. Patricia Garnica MS, ANP-BC, CDE, CDTC Inpatient Diabetes Nurse Practitioner North
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationAchieving Glycemic Control: When Optimized Basal Insulin Isn t Adequate
Achieving Glycemic Control: When Optimized Basal Insulin Isn t Adequate AAFP State Chapter Meeting Faculty Louis Kuritzky MD Clinical Assistant Profess Emeritus Department of Community Health and Family
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationWhat s New on the Horizon: Diabetes Medication Update
What s New on the Horizon: Diabetes Medication Update Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors, and what s coming Revised ADA/EASD and AACE guidelines:
More informationSelecting GLP-1 RA Treatment
Selecting GLP-1 RA Treatment Dr Felicity Kaplan March 2017 Objectives Review the progressive nature of type 2 diabetes Understand the need for timely treatment intensification Examine the place of GLP-1
More informationDisclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
More informationIncredible Incretins Abby Frye, PharmD, BCACP
Incredible Incretins Abby Frye, PharmD, BCACP Objectives & Disclosures Review the pathophysiology of T2DM and the impact of the incretin system Describe the defining characteristics of the available glucagonlike
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy Clinical Associate, Medical
More informationSGLT2 Inhibition in the Management of T2DM: Potential Impact on CVD Risk
Managing Diabetes & CVD: Expling New Evidence & Opptunities ESC Congress, London, UK 30 August, 2015 SGLT2 Inhibition in the Management of T2DM: Potential Impact on CVD Risk Silvio E. Inzucchi MD Yale
More informationWhat s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA
What s New on the Horizon: Diabetes Medication Update Michael Shannon, MD Providence Endocrinology, Olympia WA 1 Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors,
More informationType 2 Diabetes Management: Case 1: Reducing Hypoglycemic Risk Case 2: Reducing Cardiovascular Risk
Type 2 Diabetes Management M. Susan Burke, MD, FACP Clinical Associate Professor of Medicine Sidney Kimmel Medical College at Thomas Jefferson University Senior Advisor, Lankenau Medical Associates Lankenau
More informationErtugliflozin (Steglatro ) 5 mg daily. May increase to 15 mg daily. Take in the morning +/- food. < 60: Do not initiate; discontinue therapy
Sodium-glucose Cotransporter-2 (SGLT2) s Inhibit SGLT in proximal renal tubules, reducing reabsorption of filtered glucose from tubular lumen Lowers renal threshold for glucose à increase urinary excretion
More informationWhat s New in Diabetes Treatment. Disclosures
What s New in Diabetes Treatment Shiri Levy M.D. Henry Ford Hospital Senior Staff Physician Service Chief, West Bloomfield Hospital Endocrinology, Metabolism, Bone and Mineral Disorders Disclosures None
More informationGLP-1 Receptor Agonists and SGLT-2 Inhibitors. Debbie Hicks
GLP-1 Receptor Agonists and SGLT-2 Inhibitors Debbie Hicks Prescribing and Adverse Event reporting information is available at this meeting from the AstraZeneca representative The views expressed by the
More informationWhat to Do After Basal Insulin
BasalINSULIN What to Do After Basal Insulin 3 Treatment Strategies for Type 2 Diabetes These strategies can help you optimize glucose control in your patient with type 2 diabetes when basal insulin alone
More information9/29/ Disclosure. Learning Objectives. Diabetes Update: Guidelines, Treatment Options & Trends
+ Diabetes Update: Guidelines, Treatment Options & Trends Melissa Max, PharmD, BC-ADM, CDE Assistant Professor of Pharmacy Practice Harding University College of Pharmacy + Disclosure Conflicts Of Interest
More informationSide Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors. Bryce Fukunaga PharmD April 25, 2018
Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors Bryce Fukunaga PharmD April 25, 2018 Objectives For each drug class: Identify the overall place in therapy Explain the mechanism of action
More informationWhat s New in Diabetes Medications. Jena Torpin, PharmD
What s New in Diabetes Medications Jena Torpin, PharmD 1 Objectives Discuss new medications in the management of diabetes Understand the mechanism of the medications discussed Understand the side effects
More informationA Practical Approach to the Use of Diabetes Medications
A Practical Approach to the Use of Diabetes Medications Juan Pablo Frias, M.D., FACE President, National Research Institute, Los Angles, CA Clinical Faculty, University of California, San Diego, CA OUTLINE
More informationUpdate on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015
Update on Therapies for Type 2 Diabetes: 2015 Angela D. Mazza, DO July 31, 2015 Objectives To present the newer available therapies for the management of T2D To discuss the advantages and disadvantages
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationAlbiglutide, a Once-Weekly GLP-1RA, for the Treatment of Type 2 Diabetes
St. Onge et al. Medical Research Archives, vol. 5, issue 11, November 2017 issue Page 1 of 10 REVIEW ARTICLE Albiglutide, a Once-Weekly GLP-1RA, for the Treatment of Type 2 Diabetes Erin St. Onge 1*, Shannon
More informationExploring Non-Insulin Therapies in Type 1 Diabetes
Exploring Non-Insulin Therapies in Type 1 Diabetes Susan Cornell, BS, PharmD, CDE, FAPhA, FAADE Associate Professor Midwestern University - Chicago College of Pharmacy Disclosures Dr. Cornell: Advanced
More informationThe first stop for professional medicines advice
London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1 receptor analogues The first stop for professional medicines advice 1 London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1
More informationBasal & GLP-1 Fixed Combination Use
Basal & GLP-1 Fixed Combination Use Michelle M. Mangual, MD Diplomate of the American board of Internal Medicine and Endocrinology, Diabetes and Metabolism San Juan City hospital Learning Objectives o
More informationDisclosures. Objectives. Objectives. Maximizing the Role of GLP-1 Agonists in Our Patients with. Incretin Glucose Regulation
Disclosures Maximizing the Role of GLP-1 Agonists in Our Patients with Type 2 Diabetes Curtis L. Triplitt, Pharm.D., CDE Associate Director, Diabetes Research Center, Texas Diabetes Institute Associate
More informationMOA: Long acting glucagon-like peptide 1 receptor agonist
Alexandria Rydz MOA: Long acting glucagon-like peptide 1 receptor agonist Increases glucose dependent insulin secretion Decreases inappropriate glucagon secretion Increases β- cell growth and replication
More informationTreating Diabetes To Lower Cardiovascular Disease Risk
Treating Diabetes To Lower Cardiovascular Disease Risk Anne Peters, MD Profess, USC Keck School of Medicine Direct, USC Clinical Diabetes Programs Disclosure of Financial Relationships 2015 Consultantship
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationThe Death of Sulfonylureas? A Review of New Diabetes Medications
The Death of Sulfonylureas? A Review of New Diabetes Medications Kelly Hoenig, Pharm.D., BCPS Cedar Rapids Family Medicine Residency 2/4/17 Objectives Review GLP-1 Agonists, DPP-IV Inhibitors and SGLT-2
More informationIndividualizing Care for Patients with Type 2 Diabetes
Individualizing Care for Patients with Type 2 Diabetes Disclosures Speaker: AstraZeneca, Novo Nordisk, BI/Lilly, Valeritas, Takeda Advisor: Tandem Diabetes, Sanofi Objectives Develop individualized approaches
More informationApproaches to Addressing Incretin Deficiency. Non-Insulin Injectable Agents. Incretin Mimetics. Exendin-4 in the Gila Monster
Non-Insulin Injectable Agents Approaches to Addressing Incretin Deficiency Longer-acting analogs? (Incretin mimetics) GLP-1 Analogs Inhibition of inactivation? (Incretin enhancers) DPP-4 Inhibitors Drucker
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationInjectable Agents for Type 2 Diabetes. Richard Christensen, MD AACE Diabetes Day, Boise, ID September 2017
Injectable Agents for Type 2 Diabetes Richard Christensen, MD AACE Diabetes Day, Boise, ID September 2017 Financial Disclosures Sanofi speaker honoraria No other relevant financial disclosures Injectable
More informationNew and Emerging Therapies for Type 2 DM
Dale Clayton MHSc, MD, FRCPC Dalhousie University/Capital Health April 28, 2011 New and Emerging Therapies for Type 2 DM The science of today, is the technology of tomorrow. Edward Teller American Physicist
More informationADA and AACE Glycemic Targets
ADA and AACE Glycemic Targets HbA1C target should be individualized based on a number of factors including: Age Life expectancy Comorbidities Duration of diabetes Risk of hypoglycemia Patient motivation
More informationUpdate on Insulin-based Agents for T2D
Update on Insulin-based Agents for T2D Injectable Therapies for Type 2 Diabetes Mellitus (T2DM) and Obesity This presentation will: Describe established and newly available insulin therapies for treatment
More informationType 2 DM in Adolescents: Use of GLP-1 RA. Objectives. Scope of Problem: Obesity. Background. Pathophysiology of T2DM
Type 2 DM in Adolescents: Use of GLP-1 RA Objectives Identify patients in the pediatric population with T2DM that would potentially benefit from the use of GLP-1 RA Discuss changes in glycemic outcomes
More information3/8/2011. Julie M. Sease, Pharm D, BCPS, CDE Associate Professor of Pharmacy Practice Presbyterian College School of Pharmacy
Summarize revisions to the 2011 American Diabetes Association clinical practice guidelines. Evaluate bromocriptine as a therapeutic option in the management of type 2 diabetes. Compare and contrast the
More information9/6/18. Clinical Updates for Nurse Practitioners and Physician Assistants: Faculty. Disclosures
Clinical Updates for Nurse Practitioners and Physician Assistants: 218 Combination Basal Insulin and GLP-1 RA Therapy: A Physiologic Approach to Diabetes Care Faculty Robert S. Busch, MD, FACE Director
More informationIncretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,
More informationPharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17
Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)
More informationCurrent Clinical Practice Guideline for Diabetes Management
Current Clinical Practice Guideline for Diabetes Management Chaicharn Deerochanawong M.D. Professor of Medicine, i Rangsit Medical University it Diabetes and Endocrinology Unit Department of Medicine Rajavithi
More informationSyllabi/Slides for this program are a supplement to the live CME session and are not intended for other purposes.
Learning Objectives Understand and appropriately individualize treatments based on evidencebased guideline recommendations across the continuum of care in patients with T2DM Key = Clinical Pearl Identify
More informationExploring Non-Insulin Therapies in Type 1 Diabetes. Objectives. Pre-Assessment Question #1. Disclosures
Exploring Non-Insulin Therapies in Type 1 Diabetes Disclosures Dr. Cornell: Advanced Practitioner Advisory Board and Speakers Bureau: Novo Nordisk Susan Cornell, BS, PharmD, CDE, FAPhA, FAADE Associate
More informationOptimizing Treatment Strategies to Improve Patient Outcomes in the Management of Type 2 Diabetes
Optimizing Treatment Strategies to Improve Patient Outcomes in the Management of Type 2 Diabetes Philip Raskin, MD Professor of Medicine The University of Texas, Southwestern Medical Center NAMCP Spring
More informationNew Drug Evaluation: Dulaglutide
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationADA/EASD Guidelines. Simon Heller. University of Sheffield
ADA/EASD Guidelines Simon Heller University of Sheffield Presenter Disclosure Advisy Board Member: Eli Lilly, NovoNdisk, Sanofi Aven
More informationDiabetes Mellitus II CPG
1 Diabetes Mellitus II CPG Candidates for Screening Integrated Complex Care Patients: Check Yearly Prediabetes: Check Yearly No Diabetes Mellitus (DM) Risk Factors: Check at Age 45, Repeat Every 3 Years
More informationApplication of the Diabetes Algorithm to a Patient
Application of the Diabetes Algorithm to a Patient Apply knowledge gained from this activity to improve disease management and outcomes for patients with T2DM and obesity Note: The cases in this deck represent
More informationNew Treatment Options for Type 2 Diabetes: Incretin-Based Therapy
New Treatment Options for Type 2 Diabetes: Incretin-Based Therapy New Treatment Options for Type 2 Diabetes: Incretin-Based Therapy is supported by an educational grant from Novo Nordisk Inc. This program
More informationInitiation and Titration of Insulin in Diabetes Mellitus Type 2
Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Greg Doelle MD, MS April 6, 2016 Disclosure I have no actual or potential conflicts of interest in relation to the content of this lecture.
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Gretchen Ray, PharmD, PhC, BCACP, CDE Associate Professor, UNM College of Pharmacy January 28, 2018 gray@salud.unm.edu OBJECTIVES Describe the most
More informationMYTH VS FACT #1: GLP-1 RECEPTOR AGONISTS SHOULD BE RESERVED FOR PATIENTS WITH LONG-STANDING T2DM
9:45 11: AM Separating Myth from Fact: The Role of Receptor Agonists for the Treatment of T2DM SPEAKERS James R. Gavin, III, MD, PhD John E. Anderson, MD Presenter Disclosure Information The following
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationLearning Objectives. Impact of Diabetes II UPDATES IN TYPE 2 DIABETES. David Doriguzzi, PA-C
UPDATES IN TYPE 2 DIABETES David Doriguzzi, PA-C Learning Objectives Upon completion of this educational activity, the participant should be able to: Overcome barriers and attitudes that limit Clinician/Patient
More informationUpdate on Insulin-based Agents for T2D. Harry Jiménez MD, FACE
Update on Insulin-based Agents for T2D Harry Jiménez MD, FACE Harry Jiménez MD, FACE Has received honorarium as Speaker and/or Consultant for the following pharmaceutical companies: Eli Lilly Merck Boehringer
More informationNEW DIABETES CARE MEDICATIONS
NEW DIABETES CARE MEDICATIONS James Bonucchi DO, ECNU, FACE Adult Medicine and Endocrinology Specialists Disclosures Speakers bureau Sanofi AZ BI Diabetes Diabetes cost ADA 2017 data Ever increasing disorder.
More informationEmerging Challenges in Primary Care: GLP-1 Receptor Agonists: New Insights and New Strategies for Successful Long-Term Diabetes Management
Emerging Challenges in Primary Care: 2017 GLP-1 Receptor Agonists: New Insights and New Strategies for Successful Long-Term Diabetes Management 1 Faculty Richard S. Beaser, MD Senior Staff Physician, Medical
More informationOBJECTIVES 4/7/2014. Diabetes Update Overview of the Diabetes Epidemic in the United States. ISHP Annual Spring Meeting
Diabetes Update 2014 ISHP Annual Spring Meeting Hayley Miller MD April 13, 2014 OBJECTIVES Review diabetes guidelines. Understand diabetes management targets. Discuss current therapeutic strategies. Overview
More informationBrigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol
Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol *Please note that this guideline may not be appropriate for all patients
More informationTimely!Insulinization In!Type!2! Diabetes,!When!and!How
Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for
More informationNewer and Expensive treatment of diabetes. Endocrinology Visiting Associate Professor Institute of Medicine TUTH
Newer and Expensive treatment of diabetes Jyoti Bhattarai MD Endocrinology Visiting Associate Professor Institute of Medicine TUTH Four out of every five people with diabetes now live in developing countries.
More informationAdlyxin. (lixisenatide) New Product Slideshow
Adlyxin (lixisenatide) New Product Slideshow Introduction Brand name: Adlyxin Generic name: Lixisenatide Pharmacological class: Glucagon-like peptide-1 (GLP-1) receptor agonist Strength and Formulation:
More informationWhat s New? An Antihyperglycemic Medications Update
What s New? An Antihyperglycemic Medications Update WADE 2016 Annual Conference Josh Neumiller, PharmD, CDE, FASCP Associate Professor Department of Pharmacotherapy Washington State University Disclosures
More informationUKPDS: Over Time, Need for Exogenous Insulin Increases
UKPDS: Over Time, Need for Exogenous Insulin Increases Patients Requiring Additional Insulin (%) 60 40 20 Oral agents By 6 Chlorpropamide years, Glyburide more than 50% of UKPDS patients required insulin
More information3/22/2017. Type 2 Diabetes Pathophysiology and Pharmacology Review. Accreditation Statement
Type 2 Diabetes Pathophysiology and Pharmacology Review Joshua J. Neumiller, PharmD, CDE, FASCP Vice Chair & Associate Professor, Department of Pharmacotherapy Washington State University Spokane, WA This
More informationLet s not sugarcoat it! Update on Pharmacologic Management of Type II DM
Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM Gregory Castelli, PharmD, BCPS, BC-ADM Clinical Pharmacist UPMC St. Margaret Objectives By the end of this presentation, participants
More informationThe Diabetes Guidelines Trek: The Next Generation. Inpatient Diabetes Guidelines. Learning Objectives. Current Inpatient Guidelines
The Diabetes Guidelines Trek: The Next Generation J. Christopher Lynch, PharmD, BCACP Southern Illinois University Edwardsville School of Pharmacy Susan Cornell BS, PharmD, CDE, FAPhA, FAADE Midwestern
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationSoliqua (insulin glargine and lixisenatide), Xultophy (insulin degludec and liraglutide)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.48 Subject: Insulin GLP-1 Combinations Page: 1 of 5 Last Review Date: September 15, 2017 Insulin GLP-1
More information7/6/ ANNUAL MEETING DIABETES - KEEPING UP WITH CHANGES TECHNICIAN OBJECTIVES PROJECTED PREVALENCE OF DIABETES IN THE UNITED STATES:
TECHNICIAN OBJECTIVES Audience will be able to describe the differences between traditional and newer insulin products. DIABETES - KEEPING UP WITH CHANGES MARY HENCHER PHARMD, BCPS, CDE CLINICAL PHARMACIST,
More information